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The insulin-like growth factor (IGF-1) signalling is highly implicated in cancer. In this signalling the IGF-1 receptor (IGF-1R) is
unquestionable, the predominating single factor. IGF-1R is crucial for tumour transformation and survival of malignant cell, but is only
partially involved in normal cell growth. This is in part due to the interactions with oncogenes. Recent findings suggest a close interplay
with the p53/MDM2 pathway. Disturbances in components in the p53/MDM2/IGF-1R network may cause IGF-1R upregulation and
growth advantage for the cancer cell. Targeting of IGF-1R is more and more seen as a promising option for future cancer therapy.
Single chain antibodies and small molecules with selective effects on IGF-1R dependent malignant growth are of particular interest.
Forthcoming clinical trials are welcome and will indeed be the only way to evaluate the impact of IGF-1R targeting in human cancer.
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Mounting of evidence provided during the 10 last years implicates
a crucial role of insulin-like growth factor 1 (IGF-1) signalling in
development and progression of cancer. The most important single
component in this signalling, involving the ligands IGF-1 and
IGF-2, several binding proteins, proteases as well as three recep-
tors, is the IGF-1 receptor (IGF-1R). In this review we will
summarise relevant studies on the role of IGF-1R in cancer with
focus on: (1) the unique role of IGF-1R signalling in malignant
cells; (2) the interactions between IGF-1R and tumour suppressor
genes and proto-oncogenes; as well as (3) current attempts in
targeting the IGF-1R as a potential option in cancer therapy.
UNIQUE ROLE OF IGF-1R IN CANCER
The IGF-1R is a phylogenetically conserved receptor TK and
belongs to the insulin receptor family, involving also the insulin
receptor (IR), hybrid receptors and the IGF-2R/mannose 6-
phosphate receptor. The function of the hybrid receptor is still
not well understood. The IGF-2R/6-mannose receptor is a
monomeric receptor without TK activities. Both IGF-1R and IR
are preformed dimeric TK receptors made up by two extracellular
a-subunits and two b-subunits involving a small extracellular
domain, an intramembraneous one as well as an intracellular
domain (Adams et al, 2000). The latter includes the juxtamem-
braneous domain, the TK domain and the C-terminal domain. The
IGF-1R and IR are highly homologous, especially in the TK domain
in which they share 84% amino-acid identities. However, despite
these similarities, the functions between IGF-1R and IR differ
considerably. The IGF-1R is mainly involved in regulation of cell
proliferation, antiapoptosis, differentiation and cell motility,
whereas IR is mostly of impact for control of glucose uptake and
metabolism. However, the isoform A (exon 11-splice variant) of IR
(IR-A), normally expressed in fetal tissues, promotes cell growth in
response to IGF-2 stimulation and has been reported to be
abundantly expressed in some IGF-1R deficient leiomyosarcomas
(Sciacca et al, 2002).
The ligandreceptor interaction results in phosphorylation of
tyrosine residues in the IGF-1R TK domain (spanning amino acid
9731229) of the b-subunit. The crystal structure of the inactive
and phosphorylated kinase domain of the IGF-1R has provided a
molecular model of the IGF-1R catalytic activity (Favelyukis et al,
2001). In unstimulated state, the activation loop (a-loop), contain-
ing the critical tyrosine (Y) residues 1131, 1135 and 1136, behaves
as a pseudosubstrate that blocks the active site. Y1135 (being the
first tyrosine to be phosphorylated after stimulation with ligand) in
the a-loop is bound in cis position in the active site, thus
preventing the substrate access and occluding the ATP binding site
as well. After ligand binding, the three tyrosines of the a-loop are
transphosphorylated by the dimeric subunit partner. Phosphory-
lation of Y1135 and Y1131 destabilises the autoinhibitory
conformation of the a-loop, whereas phosphorylation of Y1136
stabilises the catalytically optimised conformation of it (Favelyukis
et al, 2001). These changes of the a-loop conformation allow the
substrate and ATP access, further increasing the intrinsic TK
activity towards phosphorylation of other tyrosines in the receptor
and subsequently of exogenous substrate proteins. In turn,
phosphorylation of the adaptor proteins insulin receptor substrate
14 (IRS-14) and Shc leads to activation of the phosphatidyl
inositol-3 kinase (PI3K), the mitogen-activated protein kinase
(MAPK) and the 14-3-3 pathways (Baserga, 2000).
In contrast to IR, IGF-1R is ubiquitously expressed in tissues in
which it plays a role in tissue growth, mostly via the growth
hormone, which liberates IGF-1 to activate the IGF-1R. Although
this impact in normal growth, strong evidence has been provided
that IGF-1R is not an absolute requirement for normal growth,
only partially (Baserga, 1999).
On the other hand, IGF-1R has been shown to be crucial for
anchorage independent growth, a property being well established
to be unique for malignant cells. Classic experiments performed
in Baserga’s laboratory have demonstrated that anchorage
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cell surface is increased to certain amount (Baserga, 1999). The
critical role of IGF-1R in anchorage independent growth has been
confirmed in several other laboratories. This property of IGF-1R
also implicates the function of this receptor in tumour progression
since the degree of anchorage independency reflects the level of
malignancy. This means that metastasis has acquired more
anchorage independency, and more IGF-1R dependency, com-
pared to the primary tumour.
Several studies, both experimental and clinical, have demon-
strated that the IGF-1R is overexpressed compared to normal
tissues (Belfiore et al, 1999; Xie et al, 1999; All-Ericsson et al,
2002). Furthermore, epidemiological prospective studies have
identified high plasma levels of IGF-1 as a potential risk factor
for several malignancies (Hankinson et al, 1998). In addition, IGF-
2, whose expression normally is strictly controlled by parental
imprinting is upregulated and functions as an important stimulant
of the IGF-1R in cancer (LeRoith and Roberts, 2003). Thus,
upregulation of IGF-1R and its ligands are probably important
events for the malignant cell growth.
Another aspect on a unique role of IGF-1R in cancer is based on
several recent findings that loss of suppressor oncogenes as well
as activation of proto-oncogenes is related to IGF-1R function and
activity (Baserga, 1994; Girnita et al, 2000; Werner and Le Roith,
2000; Werner et al, 2000; Girnita et al, 2003; Zhao et al, 2004). This
area of research deserves a separate attention and is discussed in
the next section of this review.
Interactions between IGF-1R and oncogenes
The IGF-1R gene is constitutively expressed in most cells. The
promoter of IGF-1R is CG-rich and lacks TATA and CCAAT
elements (LeRoith et al, 1995b), but has elements found in
housekeeping genes, containing regulatory elements characteristic
for highly regulated genes (Werner et al, 1991). The IGF-1R
promoter exhibits a high basal transcriptional activity, and is
under physiological control of nutritional factors (Olchovsky et al,
1993), hormonal stimulation (Clarke et al, 1997) and the
developmental stage (Bondy et al, 1992). Its expression is altered
in certain diseases, including cancer (LeRoith et al, 1995a; Baserga
et al, 1997).
The IGF-1R promoter is targeted by several oncogenes.
Constitutive overexpression of the proto-oncogenes c-myb in
Balb/c-3T3 cells increases expression of both IGF-1 and IGF-1R, at
least partly through an increased transcriptional activity and in
this way abrogates the requirement for IGF-1 in the growing media
(Kim et al, 1996). The hepatitis B virus X protein is another
oncogene known to stimulate IGF-1R promoter activity (Kim et al,
1996) that may therewith play an aetiologic role in development
of hepatocellular carcinoma. Some of the oncogenes increasing
the IGF-1R promoter activity can also affect IGF-1R action by
nontranscriptional mechanisms. For instance, transformation of
human cells by the src oncogene of the Rous sarcoma virus results
in constitutive phosphorylation of the receptor b-subunit, but
addition of IGF-1 further increases the level of phosphorylation
(Werner and Le Roith, 2000).
The IGF-1R gene contains several binding sites for members of
ERG family of transcription factors. Wilms’ tumour 1 gene (WT1),
a member of this family, is a tumour suppressor gene and its
product has been shown to suppress the activity of promoters
containing WT1 binding sites. Genes with WT1 targeting
promoters include IGF-1R and IGF-2. WT1 has been shown to
bind to the IGF-1R promoter and to suppress activity (Werner
et al, 1995). Consistently, loss of WT1 activity in Wilms’ tumour
and related malignancies may result in transcriptional derepres-
sion of the IGF-1R gene (Gerald et al, 1995). Pathologic fusion of
the Ewing gene EWS to WT1 (t(11;22)(p13;q12)(EWS/WT1)) has
been shown to abrogate the tumour suppressor function of WT1
and to generate an oncogenic chimeric protein capable of binding
and activating the IGF-1R promoter (Karnieli et al, 1996).
Likewise, the suppressor oncogene p53 is capable of suppressing
the activity of the IGF-1R promoter as well as lowering the
endogenous levels of IGF-1R mRNA (Werner et al, 2000). In
addition, the transcription of the IGF-2 gene is similarly reduced
by wild-type p53 (Zhang et al, 1996). In contrast, tumour-derived,
mutant versions of p53 significantly stimulated promoter activity
(Werner et al, 1996). These data therefore suggest that upregula-
tion of IGF-1R due to loss-of-function of p53 may facilitate
selection of a malignant population of cells. However, the role of
p53 in regulation of IGF-1R seems to be more complex and
probably also involves post-transcriptional mechanisms (Girnita
et al, 2000; Lee et al, 2003). This can be exemplified by malignant
melanoma cells, most often harbouring wild-type p53 (Hussein,
2004), which exhibit overexpression of IGF-1R. Upon inhibition of
wild-type p53 in these cells, they surprisingly responded with a
drastic IGF-1R downregulation and cell death (Girnita et al, 2000).
Similar results have been obtained in other studies (Lee et al,
2003). These observations points to the action of other mecha-
nisms in the p53-dependent control of IGF-1R expression. Such a
mechanism could theoretical be mediated by the oncoprotein
MDM2, which interacts with p53 but has recently also been found
to associate with certain cell surface receptors and regulate their
functions (Shenoy et al, 2001). MDM2 is well known to strictly
control p53. Overexpression of MDM2 results in decreased level
and activity of p53 (Kubbutat et al, 1997) and provides an
alternative to a ‘p53 mutation’ in the sense that it inactivates p53.
In this way, MDM2 enables the development of tumours that retain
wild-type p53. Just, recently, it was shown that under conditions
when p53 was inhibited, MDM2 was redistributed and bound to
the IGF-1R (Girnita et al, 2003). MDM2 was proven to ubiquitinate
the IGF-1R and degraded it in a proteasome-dependent manner
(Girnita et al, 2003), eventually leading to cell death. This action of
MDM2 explains the earlier results that inhibition of wild-type p53
unexpectedly leads to downregulation of the IGF-1R (Girnita et al,
2000). These data are in consistent with several other studies
reporting apoptotic effects due to overexpressed MDM2 (Vousden
and Prives, 2005). However, drastic redistributions of MDM2 from
p53 to the IGF-1R can probably only be achieved after
experimental modulations, like inhibition of p53 expression by
antisense strategies, etc, and do not likely occur in this manner in a
physiologic context. On the other hand, an increased distribution
of MDM2 to the cell nucleus to interact with p53 may indirectly
increase the expression of IGF-1R since lesser cytoplasmic MDM2
will be available to ubiquitinate and degrade the receptor.
Unpublished studies in our laboratory have suggested that some
amounts of MDM2, by inducing ubiquitination, are important for
internalisation and activation of the IGF-1R. However, if the
MDM2 levels are becoming too abundant, the IGF-1R is over-
ubiquitinated and degraded. These findings are also interesting
from an IGF-1R targeting point of view because pharmacological
modulations leading to an excess of MDM2 could be a manner to
cause a selective IGF-1 inhibition and apoptosis in cancer cells.
Reciprocally, the IGF-1 system has been shown to influence the
activity of MDM2. IGF-1 was demonstrated to regulate MDM2
activity by inhibiting the association between p19ARF and MDM2
in a p38 MAPK-dependent manner (Heron-Milhavet and LeRoith,
2002). Thus, when IGF1 was used to rescue the cells from UV-
induced DNA damage, the p53 protein was degraded through the
MDM2-mediated pathway. Others studies indicate that expression
of phosphorylated Akt increases MDM2-mediated ubiquitination
of p53 (Mayo and Donner, 2001). The serum-induced increase in
p53 ubiquitination was blocked by a PI3K inhibitor, suggesting
that phosphorylated Akt enhances the ubiquitination-promoting
function of MDM2, determining reduction of the p53 protein.
In conclusion, there seems to exist a p53/MDM2/IGF-1R axis, in
which signals are propagated in either direction. Changes leading
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p53 may contribute with a growth advantage for the tumour cells
by upregulating the IGF-1R. This could be due to a derepressed
transcription of the IGF-1R gene as well as a decreased
ubiquitination and degradation of the receptor. A schematic
picture illustrating possible links between p53 and IGF-1R is
presented in Figure 1.
TARGETING IGF-1R IN CANCER
The vast expression of IGF-1R in neoplastic cells and tissues
combined with its crucial roles in cancer cell growth is making this
tyrosine receptor an attractive target to combat malignant diseases.
Blockade of IGF-1R has been convincingly shown to cause
massive apoptosis of tumour cells in vivo, to inhibit tumorigenesis
and block tumour invasion and metastasis. Overall, strategies
leading to downregulation of the receptor, and not only inhibition
of its TK activity, have been associated with the strongest
antitumour efficacies (Baserga et al, 2003). This may be due to
that a downregulation of IGF-1R is necessary to produce a
complete inhibition of its function.
A variety of approaches aimed at targeting IGF-1R has been
utilised to prove the concept, or are being developed for potential
anticancer therapies. Targeting of IGF-1R to block its signalling
may be obtained by interference with ligand/receptor interactions,
receptor synthesis and expression, receptor TK activity, or
combinations of these strategies.
Strategies aimed to block the ligand–receptor interaction
involve receptor neutralising antibodies (Kalebic et al, 1994).
Among those most studied is the monoclonal antibody a-IR3,
which competes with IGF-1 for binding to the receptor and blocks
receptor activation (Van Wyk et al, 1985). However, aIR3 can
sometimes act as an IGF1 mimetic and especially in cells
overexpressing the IGF-1R (Kato et al, 1993). Antibody blockade
of IGF-1R has been attempted in breast cancer model systems.
However, the large size of the therapeutic molecule restricts its
access to tumour cells, particularly in central regions of solid
tumours (Russell et al, 1992). Smaller fragments are currently
being studied as a substitute for whole antibodies in an effort to
improve access and uptake. Sachdev et al (2003) used a single-
chain antibody directed against IGF-1R (IGF-1R scFv-Fc) to
examine the effects on IGF-1R signalling. In vivo treatment of
mice bearing MCF-7 xenograft tumours with scFv-Fc resulted in
near complete downregulation of IGF-1R.
Dominant-negative mutated IGF-1R (Dunn et al, 1998; Brodt
et al, 2000) and truncated soluble IGF-1R (D’Ambrosio et al, 1996)
are two related strategies to block IGF-1R. D’Ambrosio et al
engineered by a frame-shift mutation a human IGF-1R cDNA that
produces 486 amino acids long receptor. This truncated soluble
receptor inhibited the autophosphorylation of the endogenous
IGF-1R as well as induced extensive apoptosis in vivo and
inhibited tumorigenesis in syngeneic rats. From a therapeutic
point of view, these strategies suffer from the problem how to
administrate these molecules to receive an efficient uptake in the
tumour cells.
Antisense techniques are another way to inactivate the IGF-1R.
Resnicoff et al (1994) used antisense RNA to IGF-1R by
introducing it into cells by either addition of oligodeoxynucleo-
tides or by transfection with plasmids expressing antisense RNA to
IGF-1R RNA. Injection of glioblastoma cells (C6) IGF-1R antisense
cells into rats carrying an established wild-type C6 tumour caused
complete regression of the tumours. This fact further raises the
possibility of practical applications targeting IGF-1R. Moreover,
downregulation of IGF-1R, obtained by antisense strategies, has
been reported to elicit a host response leading to eradication of
surviving malignant cells in vivo (Resnicoff et al, 1996). Interest-
ingly, in a pilot study, exposure of autologous glioma cells treated
ex vivo with IGF-1R antisense oligos induced partial tumour
regression in some patients with malignant astrocytoma (Andrews
et al, 2001). This response seems to be immunogenic, involving the
MHC I system, but is still not closer characterised.
A direct strategy to interfere with IGF-1R activity is to induce
selective inhibition of its TK by developing selective small-
molecular inhibitors. The major advantage of this approach is
that small molecules have a considerable higher bioavailability
compared to antibodies, dominant-negative receptors and anti-
sense oligonucleotides. However, TK inhibitors face the problem
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Figure 1 Interplay between p53, MDM2 and IGF-1R. The upper part of scheme shows that MDM2 can decrease p53 synthesis but also associate
(indicated by dotted arrows) to it. This causes ubiquitination of p53. On the right it is indicated that p19 ARF can associate (dotted arrow) to MDM2. This
prevents MDM2 association to p53.
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developed IGF-1R TK inhibitors have also caused substantial
inhibition of the IR. Such cross reaction would probably cause
diabetic reactions in patients and can therefore not be accepted.
On the other hand, IR-A dependent tumours would not be affected
by a fully selective IGF-1R inhibitor.
Most of the IGF-1R TK inhibitors produced so far have served as
competitive ATP inhibitors. Since the region of the TK domain
covering the ATP binding site is identical to that of the IR, such
cross-inhibitions are not unexpected. However, there is a recent
interesting exception. Garcia-Echeverria et al (2004) presented a
new compound (a pyrrolo[2,3-d] pyrimidine) that although
inhibiting the IGF-1R and IR TK equipotently in cell-free systems,
exhibited several-fold selectivity for the IGF-1R in a cellular
context and reduced the growth of IGF-1R positive fibrosarcomas
in vivo.
Blum et al (2003) presented a new family of bioisostere
inhibitors, based on the structure of AG 538, a tyrphostin
inhibiting the IGF-1R TK at the substrate level and not at the
ATP binding site (Blum et al, 2000). These AG 538 bioisosteres
possessed similar but weaker biological properties to AG 538 but
are more stable and blocked the formation of colonies of prostate
and breast cancer cells in soft agar systems (Blum et al, 2003).
Recently, we demonstrated that the cyclolignan PPP inhibited
phosphorylation of IGF-1R without interfering with insulin
receptor activity (Girnita et al, 2004), as well as it reduced
phosphorylated Akt, caused apoptosis and induced tumour
regression in xenografted mice. PPP did not compete with ATP
but interfered with phosphorylation in the activation loop of the
kinase domain, in which it specifically blocked phosphorylation of
the tyrosine (Y) 1136 residue, while sparing the two others (Y1131
and Y1135). Since an IGF-1R construct, in which the tyrosine at
position 1136 was replaced by a phenylalanine, also led to a strong
inhibition of phosphorylated Akt in transfected cells, it was
suggested that this mechanism may be responsible for the
apoptotic effect of PPP (Vasilcanu et al, 2004). Unpublished
studies have also demonstrated that the IGF-1Rs of PPP treated
cells are undergoing rapid downregulation. This downregulation
may be important for the strong apoptotic effect of this compound.
Table 1 summarises different approaches to target the IGF-1R.
Although a huge number of experimental and preclinical
investigations have provided encouraging results, clinical trials
must be performed and completed to definitely evaluate the
usefulness and risks of targeting IGF-1R as an option in cancer
treatment of humans.
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